drugset / Trial / NCT06917872

A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood

NCT06917872

Phase 1 Completed 20 enrolled Boehringer Ingelheim
NaSequentialOpen-labelTreatment

Summary

The main objective of this trial is to investigate the effect of erythromycin, a moderate CYP3A4 inhibitor on the pharmacokinetics of BI 1291583 at steady state.

Timeline

Start
2025-04-29
Primary completion
2025-09-09
Completion
2025-09-09

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1291583 Unknown
Subject Erythromycin Small molecule Oral

Indications

No indication recorded.